Drug Profile
Descartes 15
Alternative Names: Descartes-015; Descartes-15Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
- Preclinical Autoimmune disorders; Solid tumours
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 01 Mar 2024 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) (NCT06304636)
- 08 Jan 2024 US FDA approves IND application for Descartes 15 in Autoimmune disorders and Multiple myeloma
- 08 Jan 2024 Pharmacodynamics and pharmacokinetics data from preclinical studies in Multiple myeloma released by Cartesian Therapeutics